Related Experiment Video
Updated: Mar 11, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
19.5K
Using Group Medical Visits With Those Who Have Diabetes: Examining the Evidence
Laura M Housden1, Sabrina T Wong2
1University of British Columbia School of Nursing, T201 2211 Wesbrook Mall, Vancouver, BC, V6T 2B5, Canada. Laura.Housden@telus.net.
Current Diabetes Reports
|December 3, 2016
Summary
Group medical visits (GMVs) improve diabetes care outcomes and may reduce healthcare system strain. Further research is needed on quality of life, cost-effectiveness, and patient suitability for GMVs.
Area of Science:
- Diabetes Management
- Healthcare Delivery Systems
- Preventive Medicine
Background:
- Rising global diabetes prevalence necessitates innovative healthcare models.
- Conventional one-on-one primary care may not adequately address all patient needs.
- Group medical visits (GMVs) offer an alternative delivery method.
Purpose of the Study:
- To evaluate the impact of GMVs on diabetes patient outcomes.
- To explore the effects of GMVs on healthcare systems.
- To identify areas for future research regarding GMVs.
Main Methods:
- Analysis of existing evidence on GMVs for diabetes.
- Review of studies examining physiologic and self-care outcomes.
- Examination of literature on systems-level impacts and patient-reported outcomes.
Main Results:
- GMVs demonstrate positive effects on HbA1c, blood pressure, and self-management skills.
- Evidence suggests GMVs enhance prevention strategies and may reduce ER visits and hospitalizations.
- Gaps exist in understanding GMVs' impact on quality of life, cost-savings, and patient-specific factors.
Conclusions:
- GMVs show promise for improving diabetes care and healthcare efficiency.
- Further investigation is required to optimize GMV implementation and assess broader patient benefits.
- Understanding patient barriers and identifying ideal candidates for GMVs is crucial.
More Related Videos
Related Concept Videos
01:15Diabetes: Management and Pharmacotherapy
1.2K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.2K
01:22Diabetes Mellitus: Type 2 and Gestational
5.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.3K
01:15Diabetes: Symptoms, Diagnosis, and Complications
2.6K
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
2.6K
01:22Diabetes Mellitus: Overview and Type I Subtype
5.7K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
5.7K
01:15Hypoglycemia and Glucagon
1.1K
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.1K
01:06Oral Hypoglycemic Agents: Glinides
789
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
789